Resistance of human fungal pathogens to antifungal drugs.

Resistance mechanisms can be engaged in clinically relevant fungal pathogens under different conditions when exposed to antifungal drugs. Over past years, active research was undertaken in the understanding of the molecular basis of antifungal drug resistance in these pathogens, and especially against the class of azole antifungals. The isolation of various alleles of the gene encoding the target of azoles has enabled correlation of the appearance of resistance with distinct mutations. Resistance mechanisms to azoles also converge to the upregulation of multidrug transporter genes, whose products have the capacity to extrude from cells several chemically unrelated antifungal agents and toxic compounds. Genome-wide studies of azole-resistant isolates are now permitting a more comprehensive analysis of the impact of resistance on gene expression, and may deliver new clues to their mechanisms. Several laboratories are also exploring, as well as possible alternative resistance pathways, the role of biofilm formation by several fungal species in the development of resistance to various antifungals, including azoles.

[1]  Mahmoud A. Ghannoum,et al.  Biofilm Formation by the Fungal PathogenCandida albicans: Development, Architecture, and Drug Resistance , 2001, Journal of bacteriology.

[2]  K. Ziegelbauer,et al.  Multiple Functions of Pmt1p-mediated ProteinO-Mannosylation in the Fungal Pathogen Candida albicans * , 1998, The Journal of Biological Chemistry.

[3]  T. C. White,et al.  Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  T. C. White,et al.  Homozygosity at the Candida albicans MTL locus associated with azole resistance. , 2002, Microbiology.

[5]  T. C. White,et al.  Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance , 1998, Clinical Microbiology Reviews.

[6]  D. Kontoyiannis,et al.  Antifungal drug resistance of pathogenic fungi , 2002, The Lancet.

[7]  T. C. White,et al.  Rapid, Transient Fluconazole Resistance inCandida albicans Is Associated with Increased mRNA Levels of CDR , 1998, Antimicrobial Agents and Chemotherapy.

[8]  M. Bard,et al.  Sequencing, Disruption, and Characterization of the Candida albicans Sterol Methyltransferase (ERG6) Gene: Drug Susceptibility Studies in erg6 Mutants , 1998, Antimicrobial Agents and Chemotherapy.

[9]  J. Wingard,et al.  Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia , 1997, Antimicrobial agents and chemotherapy.

[10]  E. Mellado,et al.  Identification of Two Different 14-α Sterol Demethylase-Related Genes (cyp51A and cyp51B) in Aspergillus fumigatus and Other Aspergillus species , 2001, Journal of Clinical Microbiology.

[11]  D. Sanglard,et al.  A common drug‐responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance , 2002, Molecular microbiology.

[12]  M. Raymond,et al.  Functional isolation of the Candida albicans FCR3 gene encoding a bZip transcription factor homologous to Saccharomyces cerevisiae Yap3p , 2001, Yeast.

[13]  J. Lopez-Ribot,et al.  Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients , 2001, Antimicrobial Agents and Chemotherapy.

[14]  K. Kuchler,et al.  Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters , 1995, Antimicrobial agents and chemotherapy.

[15]  D. Sanglard,et al.  Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors , 1996, Antimicrobial agents and chemotherapy.

[16]  D. Sanglard,et al.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. , 1997, Microbiology.

[17]  B. Wickes,et al.  Biofilm Formation by Candida dubliniensis , 2001, Journal of Clinical Microbiology.

[18]  C. Beck-Sague,et al.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.

[19]  D. Denning,et al.  Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. , 2002, Fungal genetics and biology : FG & B.

[20]  J. Morschhäuser,et al.  Targeted gene disruption in Candida albicans wild‐type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates , 2000, Molecular microbiology.

[21]  D. Sanglard,et al.  Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. , 2002, The Lancet. Infectious diseases.

[22]  G. Köhler,et al.  Activation of the Multiple Drug Resistance GeneMDR1 in Fluconazole-Resistant, Clinical Candida albicans Strains Is Caused by Mutations in atrans-Regulatory Factor , 2000, Journal of bacteriology.

[23]  M. Raymond,et al.  AP1-mediated Multidrug Resistance in Saccharomyces cerevisiae Requires FLR1 Encoding a Transporter of the Major Facilitator Superfamily* , 1997, The Journal of Biological Chemistry.

[24]  V. Gupta,et al.  Identification of polymorphic mutant alleles of CaMDR1, a major facilitator of Candida albicans which confers multidrug resistance, and its in vitro transcriptional activation , 1998, Current Genetics.

[25]  E. Manavathu,et al.  Comparative Study of Susceptibilities of Germinated and Ungerminated Conidia of Aspergillus fumigatus to Various Antifungal Agents , 1999, Journal of Clinical Microbiology.

[26]  S. Kelly,et al.  Molecular basis of resistance to azole antifungals. , 2002, Trends in molecular medicine.

[27]  S. Donnelly,et al.  Identification and Expression of Multidrug Transporters Responsible for Fluconazole Resistance in Candida dubliniensis , 1998, Antimicrobial Agents and Chemotherapy.

[28]  Hidetoshi Takahashi,et al.  Identification of Saccharomyces cerevisiae Isoleucyl-tRNA Synthetase as a Target of the G1-specific Inhibitor Reveromycin A* , 2002, The Journal of Biological Chemistry.

[29]  M. Klepser,et al.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. , 1998, The Journal of antimicrobial chemotherapy.

[30]  T. Poulos,et al.  Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C. van Broeckhoven,et al.  Molecular biological characterization of an azole-resistant Candida glabrata isolate , 1997, Antimicrobial agents and chemotherapy.

[32]  S. Katiyar,et al.  Aspergillus fumigatus CYP51 sequence: potential basis for fluconazole resistance. , 2001, Medical mycology.

[33]  David Y. Thomas,et al.  Population genomics of drug resistance in Candida albicans , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Dierich,et al.  Studies of In Vitro Activities of Voriconazole and Itraconazole against Aspergillus Hyphae Using Viability Staining , 2001, Antimicrobial Agents and Chemotherapy.

[35]  A. Goffeau,et al.  Functional Expression of Candida albicans Drug Efflux Pump Cdr1p in a Saccharomyces cerevisiae Strain Deficient in Membrane Transporters , 2001, Antimicrobial Agents and Chemotherapy.

[36]  Dominique Sanglard,et al.  Amino Acid Substitutions in the Cytochrome P-450 Lanosterol 14α-Demethylase (CYP51A1) from Azole-Resistant Candida albicans Clinical Isolates Contribute to Resistance to Azole Antifungal Agents , 1998, Antimicrobial Agents and Chemotherapy.

[37]  D. Sanglard,et al.  Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[38]  J. Lavandera,et al.  Translation Elongation Factor 2 Is Part of the Target for a New Family of Antifungals , 1998, Antimicrobial Agents and Chemotherapy.

[39]  D. Sanglard,et al.  Role of ATP-Binding-Cassette Transporter Genes in High-Frequency Acquisition of Resistance to Azole Antifungals in Candida glabrata , 2001, Antimicrobial Agents and Chemotherapy.

[40]  B. Wickes,et al.  Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. , 2002, The Journal of antimicrobial chemotherapy.

[41]  Ronald N. Jones,et al.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans , 1997, Antimicrobial agents and chemotherapy.

[42]  D. Sanglard,et al.  The ATP Binding Cassette Transporter GeneCgCDR1 from Candida glabrata Is Involved in the Resistance of Clinical Isolates to Azole Antifungal Agents , 1999, Antimicrobial Agents and Chemotherapy.

[43]  M. Ghannoum,et al.  Mechanism of Fluconazole Resistance inCandida krusei , 1998, Antimicrobial Agents and Chemotherapy.

[44]  Yoshiharu Inoue,et al.  Regulation of the Yeast Yap1p Nuclear Export Signal Is Mediated by Redox Signal-Induced Reversible Disulfide Bond Formation , 2001, Molecular and Cellular Biology.

[45]  J. Morschhäuser,et al.  MDR1-Mediated Drug Resistance inCandida dubliniensis , 2001, Antimicrobial Agents and Chemotherapy.

[46]  T. C. White,et al.  Resistance Mechanisms in Clinical Isolates of Candida albicans , 2002, Antimicrobial Agents and Chemotherapy.

[47]  T. Hallstrom,et al.  Multiple Pdr1p/Pdr3p Binding Sites Are Essential for Normal Expression of the ATP Binding Cassette Transporter Protein-encoding Gene PDR5* , 1996, The Journal of Biological Chemistry.

[48]  M. Ghannoum,et al.  Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance , 1999, Clinical Microbiology Reviews.

[49]  D. Sanglard,et al.  Experimental Induction of Fluconazole Resistance in Candida tropicalis ATCC 750 , 2000, Antimicrobial Agents and Chemotherapy.

[50]  B. Arthington-Skaggs,et al.  Antifungal drug susceptibility testing and resistance in Aspergillus. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[51]  M. Raymond,et al.  The bZip Transcription Factor Cap1p Is Involved in Multidrug Resistance and Oxidative Stress Response inCandida albicans , 1999, Journal of bacteriology.